J Menopausal Med.  2017 Apr;23(1):1-4. 10.6118/jmm.2017.23.1.1.

Cell Therapy Products in Alzheimer Disease

• Song HJ
• Kim TH
• Lee HH
• Kim JM
• Park YJ
• Lee A
• Kim SA
• Choi HJ

• KMID: 2378218
• DOI: http://doi.org/10.6118/jmm.2017.23.1.1

Abstract

We are rapidly becoming an aging society, with the ongoing increase in challenges of the elderly. The age-related cognitive decline in accordance with aging society is of major importance in public health. Recent studies have proved the impacts of sex-steroid hormone on the brain; compliant with aging, menopause and decrease in estrogen have an effect on the occurrence and prevention of Alzheimer's disease. A new hypothesis states that Alzheimer's disease is a postmenopausal dementia, and is a negative form of estrogen deficiency. In this review article, we reckoned the cause of postmenopausal Alzheimer's disease. We further investigated new cell therapies for postmenopausal Alzheimer's disease, which are under development in some pharmaceutical companies. One remedy is cell therapy that inhibits the amyloid beta formation, and the other is the umbilical cord blood derived mesenchymal stem cell therapy.

Keyword

Alzheimer's disease; Cell- and tissue-based therapy; Menopause; Stem cells

MeSH Terms

Aged
Aging
Alzheimer Disease*
Amyloid
Brain
Cell- and Tissue-Based Therapy*
Dementia
Estrogens
Female
Fetal Blood
Humans
Menopause
Mesenchymal Stromal Cells
Public Health
Stem Cells
Amyloid
Estrogens

Reference

1. Jeon WK, Han CH, Kang JS, Heo EJ, Han JS, Lee YJ. Research performance evaluation based on quantitative information analysis in the field of herbal medicine for dementia treatment. J Orient Neuropsychiatry. 2011; 22:101–113.

2. Kim IK, Choi HM, Kim MH. Menopausal knowledge and management in peri-menopausal women. J Korean Soc Menopause. 2012; 18:124–131.

3. Kim T. The effects of estrogen on the cognitive function and dementia. J Korean Soc Menopause. 2006; 12:103–112.

4. Lee KB. The difference in neurotransmitter & depression scale and the sleep effect following aroma therapy in postmenopausal women and dementia patients [dissertation]. Seoul: Sookmyung Women's University;2013.

5. Park HM. Role of estrogen in senile dementia of alzheimer type. J Korean Soc Menopause. 1997; 3:99–109.

6. Kwon KJ, Lee EJ, Kim MK, Jeon SJ, Choi YY, Shin CY, et al. The potential role of melatonin on sleep deprivation-induced cognitive impairments: implication of FMRP on cognitive function. Neuroscience. 2015; 301:403–414.

7. Roh SI, Lee JY. Embryonic stem cell therapy for neurodegenerative brain diseases. Dement Neurocogn Disord. 2005; 4:68–75.

8. Lee HM, Joo BS, Lee CH, Kim HY, Ock JH, Lee YS. Effect of glucagon-like peptide-1 on the differentiation of adipose-derived stem cells into osteoblasts and adipocytes. J Menopausal Med. 2015; 21:93–103.

9. Kim S, Chang KA, Kim J, Park HG, Ra JC, Kim HS, et al. The preventive and therapeutic effects of intravenous human adipose-derived stem cells in Alzheimer's disease mice. PLoS One. 2012; 7:e45757.

10. Shin JH, Kang AR. Estetrol, E4. J Korean Soc Menopause. 2009; 15:1–7.

11. Ferger B, Shimasaki M, Ceci A, Ittrich C, Allers KA, Sommer B. Flibanserin, a drug intended for treatment of hypoactive sexual desire disorder in pre-menopausal women, affects spontaneous motor activity and brain neurochemistry in female rats. Naunyn Schmiedebergs Arch Pharmacol. 2010; 381:573–579.

12. Sang JH, Kim TH, Kim SA. Flibanserin for treating hypoactive sexual desire disorder. J Menopausal Med. 2016; 22:9–13.

13. Kim JH. Alzheimer's disease and estrogen. J Korean Soc Menopause. 2000; 6:3–11.